8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d)

of The Securities Exchange Act of 1934

July 3, 2013

HALOZYME THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Delaware	001-32335	88-0488686
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

11388 Sorrento Valley Road, San Diego, California	92121
(Address of principal executive offices)	(Zip Code)

Registrant’s telephone number, including area code: (858) 794-8889

Not Applicable

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01 Other Events.

Attached hereto as Exhibit 99.1, which is incorporated herein by reference, is a copy of the slides which formed the basis of Dr. Francisco Perez’s presentation to the 9th Annual World Congress of Cosmetic Dermatology on June 29, 2013 in Athens, Greece. Halozyme Therapeutics, Inc. may use some or all of theses slides, or the information contained in the slides, in subsequent presentations to interested parties, including analysts and stockholders.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.	Description
99.1	Gynoid Lipodystrophy (Cellulite) (Preliminary Interim Results) Presentation by Dr. Perez-Atamoros.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Halozyme Therapeutics, Inc.
July 3, 2013	By:	/s/ Jean Liu
		Jean Liu
		Vice President, General Counsel

EX-99.1

Exhibit 99.1

GYNOID LIPODYSTROPHY (CELLULITE): A PHASE 1/ 2, VEHICLE-CONTROLLED STUDY TO EVALUATE SAFETY, TOLERABILITY AND PHARMACOLOGIC EFFECT OF SUBCUTANEOUSLY INJECTED RHUCAT-L IN HEALTHY FEMALE SUBJECTS (PRELIMINARY INTERIM RESULTS) DR. FRANCISCO PEREZ ATAMOROS DERMATOLOGIST amdac@iwm.com.mx

Public Disclosure Francisco Perez-Atamoros, M.D. is the independent owner of Centro Dermatologico Tennyson where the study is being conducted. Dr Perez-Atamoros is the Principal Investigator for the study. Materials and monetary support for the study are provided by Halozyme Therapeutics, Inc. THIS IS NOT A COMMERCIAL PRODUCT.

rHuCatL: Recombinant Human Cathepsin-L Cathepsin-L: a natural human enzyme Lysosomal enzyme: active at lysosomal pH 5, but rapidly inactivated at extracellular pH 7.4 Efficient collagenase’ at pH 5.0 (~pH of lidocaine) Lysosome pH 5.0 Collagen I Type Enzyme ‘On’ Enzyme Off

Concept: Conditionally Active Enzymatic Subcission 1- Enzyme injected in active state 2- Enzyme cleaves fibrous septa 3- Enzyme inactivates as it diffuses away from injection site. 4- Dimple released as septa lysed

Phase 2, Protocol Healthy female subjects aged 18-45 with moderate to severe cellulite Double-blind randomization (right/left) for active and vehicle injection; 1cc injections into 5 dimples within 10x10 cm2 areas on each side Primary efficacy assessment is at Day 28, with additional assessments before and at Days 2, 7, 14, and at 3 and 6 months following treatment Primary endpoint is physician assessment, with secondary endpoints of subject self-evaluation and objective measures of skin topography

Safety Observations Safety profile to date: No serious or severe Adverse Events No dose-limiting toxicities Common mild to moderate transient pain at injection sites (generally bilateral) Common mild to moderate injection site bruising (typically one side) , which resolves within approximately 7-14 days Other treatment-related AEs included related mild injection site reactions (such as erythema, pruritus) Study drug and vehicle have been well tolerated

Mild Transient Bruising Pre-injection 7 Days 14 Days 28 Days

Mild Transient Bruising Pre-injection 7 Days 14 Days 28 Days

Efficacy Endpoints, Day 28 Observation Physician Assessment (Primary Endpoint) 10 of 12 subjects showed improvement Median improvement of 53%, p=.006 Subject Self-assessment 10 of 12 subjects showed improvement, p=.001 Objective Measures Primary dimple volume reduction in 10 of 12 subjects, p=.004 Treatment area skin topography in 8 of 10 evaluable subjects, p=.042

Primary Endpoint Physician Assessment 100 80 Severity 60 Cellulite 40 20 0 or e ay D ef B 28

Primary Endpoint: 53% Improvement Physician Assessment 0 Baseline -20 22% (p.009) -40 Change 53% Median -60 (p.006) % Pretreatment -80 from -100 t L ic le Ca h u e r H V Comparisons Wilcoxon signed rank test, 2-tailed, after to pre-treatment

Objective Endpoint Days 20 28 CI 10 at 4.8% Pretreatment 95% -1.3% p=.17 0 from p=.82 -8.6% Topography Mean -10 p=.042 Change Skin -20 % L le ed at ic C h at e r e V nt U Comparisons t-test, 2-tailed, after to pre-treatment

Before After rHuCatL Shallow Deep Vehicle Shallow Deep

Before After rHuCatL Shallow Deep Vehicle Shallow Deep

Positive Effect Can Be Seen In 1st Week Pre-injection 7 Days 14 Days 28 Days

Positive Response Across Treatment Area Subject 212 Pre-injection 7 Days 14 Days 28 Days

Further Improvement at 3 Months Pre-injection 28 Days 3 Months 17% 68% Improvement Improvement

Conclusions rHuCatL is being developed as a convenient, controlled enzymatic treatment for cellulite Interim data (N12) show a favorable response in 80% of subjects, median improvement is 53% 28 days after treatment Some subjects show further improvement 3 and 6 months after treatment Study drug has been well tolerated. The most common side effects were mild to moderate transient injection site pain and bruising